Skip to content

Xencor XNCR Non-Cash Royalty Revenue Related to Sale of Future Royalties

Non-Cash Royalty Revenue Related to Sale of Future Royalties at other companies

Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$181K-59.6%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.48M+76.3%
Ardelyx logo
ArdelyxARDX
-$695K+32.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$10.9M+3.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$20M+5.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$46.84M+42.0%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept xncr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's non-cash royalty revenue related to sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's non-cash royalty revenue related to sale of future royalties?
Xencor (XNCR) reported non-cash royalty revenue related to sale of future royalties of $4.42M in Q1 2026.
How has Xencor's non-cash royalty revenue related to sale of future royalties changed year-over-year?
Xencor's non-cash royalty revenue related to sale of future royalties decreased by 75.8% year-over-year, from $18.23M to $4.42M.
What does non-cash royalty revenue related to sale of future royalties mean?
This represents the non-cash revenue recognized when future royalty streams are monetized or sold upfront, often involving complex accounting for deferred revenue. It allows the company to report revenue based on the underlying performance of licensed assets despite the cash having been received in a prior period. This metric is critical for assessing the quality of earnings and the impact of financing arrangements on reported top-line growth.